Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation
- 6 November 2020
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (1) , 132-143
Abstract
Personalized medicine has been a mainstay and in practice in transplant pharmacotherapy since the advent of the field. Decisions pertaining to the diagnosis, selection, and monitoring of transplant pharmacotherapy are aimed toward the individual, the allograft, and the overall immunologic needs of the patient. Recent advances in pharmacogenomics, noninvasive biomarkers, and artificial intelligence (AI) technologies have the promise of transforming the way we individualize treatment and monitor allograft function. Pharmacogenomic testing can provide clinicians with additional data that can minimize toxicity and maximize therapeutic dosing in high‐risk patients, leading to more informed decisions that may decrease the risk of rejection and adverse outcomes related to immunosuppressive therapies. Development of noninvasive strategies to monitor allograft function may offer safer and more convenient methods to detect allograft injury. Cell free DNA and gene expression profiling offer the potential to serve as “liquid biopsies” minimizing the risk to patients and providing clinicians with useful molecular data that may help individualize immunosuppression and rejection treatment. Use of big data in transplant and novel AI platforms, such as the iBox, hold tremendous promise in providing clinicians a “glimpse into the future” thereby allowing for a more individualized approach to immunosuppressive therapy that may minimize future adverse outcomes. Advances in diagnostics, laboratory science, and AI have made the application of personalized medicine even more tailored for solid organ transplant recipients. In this perspective, we summarize the current and emerging tools available, literature supporting use, and the horizon for future personalization of transplantation.Keywords
This publication has 58 references indexed in Scilit:
- Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant RejectionScience Translational Medicine, 2014
- CYP3A4*22: Promising Newly IdentifiedCYP3A4Variant Allele for Personalizing PharmacotherapyPharmacogenomics, 2012
- Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant ConsortiumTransplantation, 2011
- Ability of pharmacy clinical decision-support software to alert users about clinically important drug—drug interactionsJournal of the American Medical Informatics Association, 2011
- The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2010
- Gene-Expression Profiling for Rejection Surveillance after Cardiac TransplantationNew England Journal of Medicine, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IIClinical Pharmacokinetics, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IClinical Pharmacokinetics, 2010
- Noninvasive Discrimination of Rejection in Cardiac Allograft Recipients Using Gene Expression ProfilingAmerican Journal of Transplantation, 2005
- Initial sequencing and analysis of the human genomeNature, 2001